Mineralocorticoid receptor (MR) antagonists have shown remarkable benefits in the treatment of cardiovascular disease. However, their underutilization in clinical practice may be attributed to concerns regarding the risk of hyperkalemia...

The heterocellular nature of the heart has been receiving increasing attention in recent years. In addition to cardiomyocytes as the prototypical cell type of the heart, non-myocytes such as endothelial...

Pulmonary hypertension (PH) is characterized by pulmonary vascular remodeling and associated with adverse outcomes. In patients with PH, plasma aldosterone levels are elevated, suggesting that aldosterone and its receptor, the...

We are proud to participate in a newly established program training the cardiovascular scientists of tomorrow: The English-language MSc Medical Sciences – Cardiovascular Research is a 1-year program, combining taught (first term)...

The ADMIRE network organizes a virtual lecture series that aims to strengthen the exchange between scientists working on aldosterone, the mineralocorticoid receptor, or related topics worldwide. The forum is open...

Epigenetic modulators have been proposed as promising new drug targets to treat adverse remodeling in heart failure. Here, we evaluated the potential of 4 epigenetic drugs, including the pan-BRD (bromodomain-containing...